A Phase I Single Arm,Open-label,Multiple Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies
Latest Information Update: 07 May 2024
At a glance
- Drugs HEC 89736 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Sponsors Sunshine Lake Pharma
- 05 May 2022 Status changed from recruiting to active, no longer recruiting.
- 07 May 2021 New trial record